Department of Emergency Medicine, Calvary Mater Newcastle, Waratah, New South Wales, Australia.
Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, Waratah, New South Wales, Australia.
J Am Soc Nephrol. 2020 Oct;31(10):2475-2489. doi: 10.1681/ASN.2020050564. Epub 2020 Sep 22.
Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was accompanied by an increase in adverse events, including severe toxicity and death. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup sought to determine the effect of and indications for extracorporeal treatments in cases of poisoning with these drugs.
We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.
A total of 44 studies (three studies, two animal studies, 28 patient reports or patient series, and 11 pharmacokinetic studies) met inclusion criteria regarding the effect of extracorporeal treatments. Toxicokinetic or pharmacokinetic analysis was available for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine). Clinical data were available for analysis from 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicity. All three drugs were classified as non-dialyzable (not amenable to clinically significant removal by extracorporeal treatments). The available data do not support using extracorporeal treatments in addition to standard care for patients severely poisoned with either chloroquine or quinine (strong recommendation, very low quality of evidence). Although hydroxychloroquine was assessed as being non-dialyzable, the clinical evidence was not sufficient to support a formal recommendation regarding the use of extracorporeal treatments for this drug.
On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning.
虽然氯喹、羟氯喹和奎宁被用于多种医疗状况,但最近的研究表明它们在治疗 COVID-19 方面可能具有一定作用。因此,处方量增加的同时,不良反应也有所增加,包括严重毒性和死亡。体外治疗中毒(EXTRIP)工作组旨在确定这些药物中毒时使用体外治疗的效果和适应证。
我们按照已发表的 EXTRIP 方法,对文献进行系统评价、筛选研究、提取数据并总结结果。
共有 44 项研究(三项研究、两项动物研究、28 项病例报告或病例系列研究以及 11 项药代动力学研究)符合关于体外治疗效果的纳入标准。有 61 名患者(13 名氯喹患者、3 名羟氯喹患者和 45 名奎宁患者)的毒代动力学或药代动力学分析结果可用。可对 38 名患者的临床数据进行分析,包括 12 名氯喹中毒患者、1 名羟氯喹中毒患者和 25 名奎宁中毒患者。所有三种药物均被归类为不可透析的(无法通过体外治疗进行临床显著清除)。现有数据不支持在标准治疗的基础上,对严重氯喹或奎宁中毒的患者使用体外治疗(强烈推荐,极低质量证据)。虽然评估羟氯喹为不可透析,但临床证据不足以支持对此药使用体外治疗的正式建议。
根据我们的系统评价和分析,EXTRIP 工作组建议不要在严重氯喹或奎宁中毒的患者中使用体外方法来增强这些药物的清除。